CEBPZ and acute myeloid leukemia: Patients with APL did not reach median EFS or OS, whereas the median EFS and OS for core binding factor AML(CBF-AML)cases were 10(95% CI 0–21)months and 13(95% CI 3–23)months, respectively, and patients with non-CBF-AML had inferior median EFS(2 months, 95% CI 1–3)and OS(2 months, 95% CI 1–3)(P<0.01).